在体内针对PTPN11驱动型白血病中的MEK和TNK2/SRC通路
bioRxiv : the preprint server for biology
|May 27, 2024
概括
结合MEK和TNK2 / SRC抑制剂显示出治疗PTPN11突变白血病如JMML和AML的前景. 这种双重治疗在临床前模型中表现出显著的疗效,提供了潜在的新治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 在PTPN11中激活突变是血液恶性瘤的驱动因素,包括青少年髓细胞白血病 (JMML) 和急性髓白血病 (AML).
- 通过PTPN11突变,RAS/MAPK通路受到失调,从而增加细胞增殖和存活率,使MEK抑制剂成为治疗标.
- 以前的研究表明,PTPN11被TNK2/SRC激酶激活,达沙替尼在PTPN11突变的JMML和AML细胞中表现出敏感性.
研究的目的:
- 为了验证联合MEK和TNK2/SRC抑制在PTPN11突变白血病中的治疗潜力.
- 在PTPN11驱动型白血病的临床前模型中评估达沙替尼 (TNK2/SRC抑制剂) 和特拉美替尼 (MEK抑制剂) 的疗效和耐受性.
主要方法:
- 开发一种在造血细胞中表达Ptpn11(D61Y) 的基因工程小鼠模型,从而导致骨髓增殖障碍.
- 用达沙替尼布和特拉美替尼布组合治疗Ptpn11(D61Y) 鼠标.
- 使用组合疗法评估患者衍生的骨髓白血病异种移植模型,具有PTPN11 F71L突变.
主要成果:
- 基因工程小鼠模型开发了一种致命的骨髓增殖性疾病,模仿人类白血病.
- 与达沙替尼布和特拉美替尼布的联合治疗与单一药物相比,在小鼠中耐受性很好,并显著减轻了疾病参数.
- 患者衍生异种移植模型也显示对组合疗法的反应有所改善.
结论:
- 联合抑制MEK和TNK2/SRC激酶是PTPN11突变白血病的一个有前途的治疗策略.
- 双重向提供了改善JMML,AML和潜在的其他PTPN11驱动的血液恶性瘤的临床益处的潜力.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K


